biostudies-literatureItaliano ANCI NIH HHS5878-87https://www.ebi.ac.uk/biostudies/studies/S-EPMC3434269biostudies-literatureUnknown118(23)<h4>Background</h4>The p53 and phosphoinositide-3-kinase, catalytic, alpha polypeptide/v-akt murine thymoma viral oncogene homolog/mechanistic target of rapamycin (PIK3CA/AKT/mTOR) pathways frequently are altered in sarcoma with complex genomics, such as leiomyosarcoma (LMS) or undifferentiated pleomorphic sarcoma (UPS). The scale of genetic abnormalities in these pathways remains unknown in angiosarcoma (AS).<h4>Methods</h4>The authors investigated the status of critical genes involved in the p53 and PIK3CA/AKT/mTOR pathways in a series of 62 AS.<h4>Results</h4>The mutation and deletion rates of tumor protein 53 (TP53) were 4% and 0%, respectively. Overexpression of p53 was detected by immunohistochemistry in 49% of patients and was associated with inferior disease-free survival. AlthoughCancerAlterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: a pattern distinct from other sarcomas with complex genomics.PMC3434269P50 CA 140146-01P01 CA047179-15A2P01 CA047179P50 CA140146Chen CLThomas RBonnet FAntonescu CRSevenet NLongy MBreen MMaki RGCoindre JMItaliano AfalseAlterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: a pattern distinct from other sarcomas with complex genomics.<h4>Background</h4>The p53 and phosphoinositide-3-kinase, catalytic, alpha polypeptide/v-akt murine thymoma viral oncogene homolog/mechanistic target of rapamycin (PIK3CA/AKT/mTOR) pathways frequently are altered in sarcoma with complex genomics, such as leiomyosarcoma (LMS) or undifferentiated pleomorphic sarcoma (UPS). The scale of genetic abnormalities in these pathways remains unknown in angiosarcoma (AS).<h4>Methods</h4>The authors investigated the status of critical genes involved in the p53 and PIK3CA/AKT/mTOR pathways in a series of 62 AS.<h4>Results</h4>The mutation and deletion rates of tumor protein 53 (TP53) were 4% and 0%, respectively. Overexpression of p53 was detected by immunohistochemistry in 49% of patients and was associated with inferior disease-free survival. Although2012-01-01T00:00:00Z2012 Dec2026-04-07T23:05:19.433Z2026-04-07T18:54:31.734ZS-EPMC34342692264890610.1002/cncr.27614